anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a facial firming anti-wrinkle mask and a preparation method thereof. In order to solve the problem that the prior product has not ideal effect and high price and has adverse reaction. The facial firming anti-wrinkle mask is made from the raw materials with the following weight proportions: 40 to 100 portions of lactoalbumin, 0.5 to 3 portions of yogurt powder and 4 to 15 portions of elm bast powder. The facial firming anti-wrinkle mask also comprises the raw materials with the following weight portions selected from: 1.5 to 5 portions of ginseng, 3 to 10 portions of saffron, 1.5 to 5 portions of liquorice, 0.5 to 3 portions of carrot and 1 to 3 portions of premna leaf protein. In the preparation method, the raw materials with the weight portions are crushed respectively to be mixed uniformly or mixed uniformly and dried; or the crushed raw materials with the weight portions are added into a mixing machine, alcohol of 50 to 70 degrees with necessary quantity is added as solvent to be heated to 70 DEG C to 80 DEG C, the raw materials are stirred completely and sent to a three-roller machine through a bottom material drain opening to be grinded; and the raw materials are put into a vacuum deaeration pot to be stirred under a constant temperature and cooled and are casted or sprayed instantly into powder for sterilizing, freezing and packing. The facial firming anti-wrinkle mask can start mechanocyte fast and promote the growth of dermal fibrocyte for benign proliferation; the facial firming anti-wrinkle mask promotes the synthesis of collagen, increases the elasticity of elastic fibers, strings drooping skin inwards and unwrinkles outwards synchronously to unwrinkle fast. The facial firming anti-wrinkle mask has the advantages of good effect, low cost and causing no adverse reaction such as hypersusceptibility etc.
FIELD: medicine, immunology. SUBSTANCE: extraction of spirituous precipitate B (Cohn's fraction III) is carried out in 10-fold volume of distilled water. For removing lipoprotein fraction chloroform and also sodium chloride were used at final concentration 0.9%, by volume. Precipitation of immunoglobulin fraction from extract is carried out in the presence of 12% polyethylene glycol. Method provides the increased purity of preparation (content of inert total proteins is decreased from 3-5% in prototype to 0-1%), specific activity is increased by 2-3-fold, the yield - by 1.5-fold and net cost - by 25%. EFFECT: enhanced purity, specific activity and yield. 1 tbl
Participants will receive placebo tablets. Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
Food Effects: When CELEBREX capsules were taken with a high fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%. Under fasting conditions, at doses above 200 mg, there is less than a proportional increase in Cmax and AUC, which is thought to be due to the low solubility of the drug in aqueous media. 

Coadministration of CELEBREX with an aluminum- and magnesium-containing antacids resulted in a reduction in plasma celecoxib concentrations with a decrease of 37% in Cmax and 10% in AUC. CELEBREX, at doses up to 200 mg twice daily, can be administered without regard to timing of meals. Higher doses (400 mg twice daily) should be administered with food to improve absorption. 

In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in Cmax, Tmax or t1/2 after administration of capsule contents on applesauce [see Dosage and Administration (2)].
PROBLEM TO BE SOLVED: To obtain a medicinal composition capable of regulating a production of tumor necrosis factors and inhibiting vascularization and activity of aminopeptidase N by making the composition contain a cyclic imide derivative. SOLUTION: This medicinal composition contains a compound or its salt expressed by the formula [Q1 is a single bond, CH2 , O, S or NH; Q2 and Q3 are each C(O), C(S) or CH2 ; Z is a single bond or a lower alkanediyl; R is a substitutable aryl or a cycloalkyl; X is nitro, an amino capable of being acylated, cyano, triflurormethyl, hydroxy, a halogen, an alkyl, etc.; (m) is 0-4] as an effective ingredient. The medicine which regulates the production of tumor necrosis factors is useful as a biological response regulator, an immune activator, an immunosuppressor, etc. The medicine which inhibits activity of aminopeptidase N is useful for preventing and curing cancers, metastases of cancers, inflammatory diseases, autoimmune diseases and allergic diseases.  The medicine which inhibits vascularization-activity is useful for preventing and curing cancers, metastases of cancers, benign tumors, chronic inflammations, psoriasis, vascularization-related eye diseases, etc.
The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
<P>PROBLEM TO BE SOLVED: To provide a cutaneous cell growth promoting composition promoting turnover of the skin by activating the cell growth in the epidermal tissue, and capable of effectively reducing or suppressing inflammation caused by ultraviolet rays.  <P>SOLUTION: The cutaneous cell growth promoting composition contains a cocoa component contained in a cacao mass as an active ingredient. Cocoa and/or the cacao mass is preferably used as the raw material containing the cocoa component. The cutaneous cell growth promoting composition preferably contains ≥1 mass% cacao mass and/or processed product thereof. At least one kind selected from a vitamin B group, vitamin C, collagen and collagen peptide is preferably contained as another component.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Children from low income families of minority status are at greater risk for development of obesity. There are no known existing treatments for pediatric obesity that focus on improving parental behaviors and the home food and activity environment. The objective of this study will be to address this limitation by developing and testing a novel treatment for low-income minority families. The objective will be attained by testing the following hypothesis: A parent-focused, home-based treatment aimed at improving parental feeding behaviors, child exposure to fruits and vegetables, and the home food and activity environment will result in significantly greater decrease in percent overweight / obesity compared to recommended practice. The hypothesis will be tested by using the approach of a pilot randomized control trial (RCT). The rationale for this aim is that success of the planned research will derive a treatment package that will provide the basis for the RCT. The planned research is expected to show the level of impact of changing parental feeding behaviors and the home environment on childhood overweight / obesity.
PURPOSE: To provide an antibody conjugate which has the immune specificness of the antigens which are the source and the whole part of the immunne activity, has others, such as a capacity to activate the complement and is useful for affinity refining, sepn., diagnosis and treatment. CONSTITUTION: The antibodies or antibody fragments (hereafter abbreviated to the antibodies) directed to the antigen parts selected from bacterium antigens, virus antigen, tumor antigens, fungus antigens, parasite virus antigens, mycoplasma antigens, differentiation antigens and antigens and histocompatible antigens are exposed to an oxidizing agent (e.g.: galastosidase, oxygen acid), by which aldehyde groups are formed in the hydrocarbon components existing outside the antibody conjugation region of the antibodies. The aldehyde groups of the hydrocarbon oxide components of the antibodies are then brought into reaction with the amine groups (e.g.: secondary amine, hydrazine, hydrazide) of the compd. or the linker covalent bonded or combined with the compd., to form the antibody complex which is suitable for in-vivo use and has the immunological reactivity and immune specificness substantially the same as those of the antibodies.
Colorectal cancer is caused by a sequence of somatic genomic alterations affecting driver genes in core cancer pathways1. Here, to understand the functional and prognostic impact of cancer-causing somatic mutations, we analysed the whole genomes and transcriptomes of 1,063 primary colorectal cancers in a population-based cohort with long-term follow-up. From the 96 mutated driver genes, 9 were not previously implicated in colorectal cancer and 24 had not been linked to any cancer. Two distinct patterns of pathway co-mutations were observed, timing analyses identified nine early and three late driver gene mutations, and several signatures of colorectal-cancer-specific mutational processes were identified. Mutations in WNT, EGFR and TGFβ pathway genes, the mitochondrial CYB gene and 3 regulatory elements along with 21 copy-number variations and the COSMIC SBS44 signature correlated with survival. Gene expression classification yielded five prognostic subtypes with distinct molecular features, in part explained by underlying genomic alterations. Microsatellite-instable tumours divided into two classes with different levels of hypoxia and infiltration of immune and stromal cells. To our knowledge, this study constitutes the largest integrated genome and transcriptome analysis of colorectal cancer, and interlinks mutations, gene expression and patient outcomes. The identification of prognostic mutations and expression subtypes can guide future efforts to individualize colorectal cancer therapy.
Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
The invention provides methods and compositions relating to an I.kappa.B kinase, IKK-.beta., and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK - .beta. encoding nucleic acids or purified from human cells. The invention provides isolated IKK-.beta. hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-.beta. genes, IKK-.beta.-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
The IL6-GP130-STAT3 pathway facilitates lung cancer progression and resistance to tyrosine kinase inhibitors. Although glycosylation alters the stability of GP130, its effect on the ligand IL6 remains unclear. We herein find that N-glycosylated IL6, especially at Asn73, primarily stimulates JAK-STAT3 signaling and prolongs STAT3 phosphorylation, whereas N-glycosylation-defective IL6 (deNG-IL6) induces shortened STAT3 activation and alters the downstream signaling preference for the SRC-YAP-SOX2 axis. This signaling shift induces epithelial-mesenchymal transition (EMT) and migration in vitro and metastasis in vivo, which are suppressed by targeted inhibitors and shRNAs against SRC, YAP, and SOX2. Osimertinib-resistant lung cancer cells secrete a large amount of deNG-IL6 through reduced N-glycosyltransferase gene expression, leading to clear SRC-YAP activation. deNG-IL6 contributes to drug resistance, as confirmed by in silico analysis of cellular and clinical transcriptomes and signal expression in patient specimens. Therefore, the N-glycosylation status of IL6 not only affects cell behaviors but also shows promise in monitoring the dynamics of lung cancer evolution.
The study is a cluster randomized controlled trial designed to evaluate the impact of RFDA intervention against current standard of care for the impact on seropositivity in children under five years, passive surveillance for confirmed malaria case incidence, and elimination of transmission from hotspots. It will be conducted among a background population of \~130,000 people in \~30,000 households in 16 health center catchment areas across several districts in Southern Province. The government of Zambia is pursuing malaria elimination as a national goal on an accelerated timeline and this trial will help evaluate two treatment-based strategies for supporting malaria elimination.

The secondary objectives of the study include: 1). Compare the effectiveness of RFDA using DHAP with RFTAT using AL in reducing rapid diagnostic test (RDT) confirmed malaria incidence through passive case detection at health facilities; 2). Compare the effectiveness of RFDA using DHAP with RFTAT using AL in reducing the prevalence of malaria and preventing re-infection in individuals receiving reactive responses; 3). Compare the cost-effectiveness of RFDA using DHAP with RFTAT using AL in reducing the burden of malaria in the community; 4). Measure the proportion of P. falciparum infections likely attributable to importation and local transmission using parasite genotyping as well as defining genotype spatial distribution; 5). Assess the utility of using serology to measure short term changes in malaria transmission and evaluate malaria elimination programs; and 6). Assess the feasibility of using remotely sensed malaria risk maps to identify areas with higher potential for local malaria transmission.
Patients receiving HSCT from a haploidentical donor. They also receive a treatment called cyclophosphamide as part of the protocol to prevent graft versus host disease at day 3 and 4 after transplantation.
PURPOSE:To obtain a device for cell culture suitable of culture of highly functional cells having high adhesion dependence and oxygen demanding cells by making constitution where a culture solution and an adjusting gas necessary for culture are made to flow in two medium channels, respectively set in contact with substance exchange membranes at both sides of culture chamber. CONSTITUTION:Cells to be cultured are packed into a culture chamber 4 and given mediums required for cell culture are made to flow in a first and a second medium channels 5 and 6 to carry out cell culture. For example, a culture solution is made to flow in the channel 5 and an adjusting gas blended with gas components necessary for the culture in the channel 6. Consequently, a fresh culture solution is fed through a substance exchange membrane 2 to culture cells at the channel 5 side and waste product from the culture cells is rapidly removed. On the other hand, since the necessary gas components are supplied through a substance exchange membrane 3 at the channel 6 side, preferable culture condition is always maintained. Consequently, preferable cell culture can be done without using a carbon dioxide gas incubator or a gas adding device like conventional method.
An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
PROBLEM TO BE SOLVED: To enable ultrasonic contrast medium image pickup for an examinee without irradiation with ultrasonic waves by forming an ultrasonic contrast medium, for which microballoons formed by enclosing gas into these shells are used, of a material which decomposes the shells with lapse of time in the living body and enclosing the gas having a pressure difference from the atm. pressure into the shells. SOLUTION: The ultrasonic contrast medium is prepd. by incorporating the microballoons BLN at a prescribed concn. into liquid LQD. The microballoons BLN are formed to hollow balls and the spherical shells SPH thereof are formed of the material which decomposes with lapse of time in the living thing and, more preferably, for example, a hydrolyzable polymer. The gas GAS, for example, air, gaseous nitrogen or carbon dioxide or the like is sealed into the spherical shells SPH. The gas GAS is enclosed under such a press which has a significant pressure difference from the atm. pressure. When such ultrasonic contrast medium is injected into the examinee, the ultrasonic waves generated with the destruction of the microballoons BLN are received and the location of the ultrasonic contrast medium in the examinee is visualized as the image.
PURPOSE: A skin care mask using hydrogel containing arazyme is provided to ensure enzyme stability and to continuously transfer arazyme efficiency. CONSTITUTION: A skin care mask of hydrogel contains arazyme. The hydrogel contains polymer and cross-linking agent. The polymer contains 2.0-4.0 weight parts of sodium polyacrylate. The cross-linking agent contains 2.0-4.0 weight parts of aluminum chloride. The hydrogel further contains purified water, glycerin, chondrus crispus, PEG-60 hydrogenated castor oil, potassium hydroxide and sodium hyaluronate. A method for manufacturing the mask comprises: a step of mixing arazyme, synthetic polymer and cross-linking agent and stirring to obtain hydrogel; and a step of making the hydrogel in a mask form.
Postoperative pneumonia (POP) is a common complication after hip fracture surgery and is associated with increased mortality and other complications in elderly patients. This study aims to evaluate biomarkers, especially the glucose-albumin ratio (GAR), for predicting POP in elderly hip fracture patients. A total of 1279 elderly patients admitted to our hospital with hip fractures were included. We assessed 29 biomarkers and focused on GAR to determine its prognostic and predictive value for POP. Multivariable logistic regression and propensity score-matched analyses were conducted to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for POP, adjusting for potential confounders. Receiver operating characteristic (ROC) curves were utilized to determine the optimal cut-off of GAR for predicting POP. Among the biomarkers and combinations assessed, GAR demonstrated superior predictive capability for POP in elderly hip fracture patients. ROC analyses showed moderate predictive accuracy of GAR for POP, with an area under the curve of 0.750. Using the optimal cut-off of 0.175, the high GAR group was significantly associated with increased odds of POP (adjusted OR 2.14, 95%, CI 1.50-3.05). These associations remained significant after propensity score matching and subgroup analyses. Dose-response relationships between GAR and POP were observed. In conclusion, GAR may be a promising biomarker to predict POP risk in elderly hip fracture patients. Further studies are warranted to validate its clinical utility. However, this study has certain limitations, including its retrospective design, potential for selection bias due to the exclusion criteria, and the single-center nature of the study, which should be addressed in future prospective, multicenter studies.
Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
This is a randomized, multicenter, placebo-controlled, double-blind study to evaluate the efficacy and safety of ULTRACET® (tramadol 37.5 mg and acetaminophen 325 mg) as add-on therapy in rheumatoid arthritis patients taking an NSAID or a COX-2 inhibitor. The patients will be randomized into 2 treatment groups: The first group will receive one ULTRACET® tablet 3 times per day for 7 days. The second group will receive one placebo tablet 3 times per day for 7 days. The primary efficacy measurement will be the patients' average daily pain score. Safety will be monitored throughout the study. The study hypothesis is that ULTRACET® will be well tolerated and the average daily pain relief score for the ULTRACET® treatment group will be better than that of placebo group. Patients will take one ULTRACET® tablet or placebo by mouth 3 times per day, for 7 days.
Sevoflurane and propofol are two basic drugs in the maintenance of anaesthesia. In this study we compared the perioperative hemodynamic parameters, recovery profiles and cost containment of sevoflurane and propofol based general anaesthesia for otorhinolaryngeal surgery. Patients were equally divided into four anaesthetic subgroups. In groups A and C anaesthesia was based on sevoflurane or propofol, respectively, without bispectral index (BIS) and train-of-for monitor (TOF) monitoring. In groups B and D anaesthesia was based on sevoflurane or propofol, respectively, with BIS and TOF monitoring. Drug consumption, recovery profiles and anaesthesia costs were analysed.

ECG, main arterial pressure (MAP), heart rate, oxygen saturation of peripheral haemoglobin (SpO2), pressure of end-tidal carbon dioxide was monitored continuously and registered at 5 min intervals during anaesthesia. Each group received propofol for anaesthesia induction. In group A and B anaesthesia was maintained with sevoflurane, in groups C and D with propofol. In groups B and D the depth of anaesthesia (BIS® Quatro Brain Monitoring Sensor, Covidien) and the neuromuscular blocking status (Infinity®, Trident® NMT SmartPod®, Dräger Medical) were monitored too. BIS and TOF values were recorded at 5 min intervals.
A secure teleconference with a patient treatment room may be initiated by receiving, at a central facility, a request for a conference from a clinician application, and then identifying a virtual meeting room and sending an identifier for a conference to the treatment room. The conference is then be established by receiving a call at the central facility from the treatment room, where the call identifies the conference. The central facility then joins the treatment room and the clinician application to the virtual meeting room. Teleconferences may thus be established without reference to sensitive patient information. For security, no incoming conferencing calls may be made to the treatment room directly, and virtual meeting rooms may be eliminated after single use. A call may further be initiated by receiving a request from the treatment room, e.g., which is processed by the central facility to alert one or more clinicians.
The invention relates to an anti-SFTSV neutralizing monoclonal antibody, the heavy chain variable region of which comprises three CDR regions, the amino acid sequences of the CDR regions are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and the light chain variable region comprises three CDR regions, the amino acid sequences of the CDR regions are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The invention also provides a medicine or vaccine containing the monoclonal antibody. The monoclonal antibody 40C10 has neutralizing antibody activity and can specifically recognize the space epitope of the SFTSV-Gn protein. The antibody can neutralize four types of strains of SFTSV and SFTSV associated virus GTV, and can be used as an SFTSV antiviral drug and used for preventing and treating the SFTSV and the GTV.
Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.